Market capitalization | $5.35b |
Enterprise Value | $5.24b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.58 |
P/S ratio (TTM) P/S ratio | 13.88 |
P/B ratio (TTM) P/B ratio | 93.68 |
Revenue growth (TTM) Revenue growth | 42.53% |
Revenue (TTM) Revenue | $385.69m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
17 Analysts have issued a Axsome Therapeutics, Inc. forecast:
17 Analysts have issued a Axsome Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 386 386 |
43%
43%
|
|
Gross Profit | 345 345 |
46%
46%
|
|
EBITDA | -245 -245 |
40%
40%
|
EBIT (Operating Income) EBIT | -252 -252 |
38%
38%
|
Net Profit | -287 -287 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Head office | United States |
CEO | Herriott Tabuteau |
Employees | 683 |
Founded | 2012 |
Website | www.axsome.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.